Материалов:
1 005 012

Репозиториев:
30

Авторов:
596 024

По вашему запросу найдено документов: 13991

Страница 1 из 1400

Modern antiandrogenic therapy of patients with castration-resistant prostate cancer without metastases
Popov S.V.
deprivation therapy for advanced prostate cancer has a time limit, after which castration resistance
Systems Oncology: Bridging Pancreatic and Castrate Resistant Prostate Cancer
Fucic A., Aghajanyan A., Culig Z., Le Novere N.
. In this paper, using examples of pancreatic ductal adenocarcinoma (PaC) and castrate-resistant prostate cancer
Second-generation androgen receptor inhibitors in therapy of non-metastatic castration resistant prostate cancer: Role of safety profile and effect on quality of life
Ushkalova E.A., Zyryanov S.K., Gopienko I.A.
of non-metastatic castration resistant prostate cancer (nmCRPC). Phase 3 trials of PROSPER (Enzalutamide
Metastatic disease of a ureter in a patient with castration-resistance prostate cancer
Nyushko K.M., Alekseev B.Ya., Kalpinskiy A.S., Golovashchenko M.P., Kaprin A.D.
Prostate cancer (PC) is a topical problem of modern urologic oncology. Castration-resistant PC
Salvage high-dose-rate brachytherapy for local recurrence of prostate cancer
Yagudaev D.M., Kadyrov Z.A., Kalinin M.R., Bezhenar V.A., Kalyagina N.A.
) in patients with local recurrence of hormone-resistant prostate cancer. High-dose rate brachytherapy allowed
Radium-223 for the treatment of patients with castration-resistant prostate cancer with bone metastases
Kaprin A.D., Kostin A.A., Vorobyev N.V., Popov S.V.
in clinical practice in patients with castration-resistant prostate cancer with bone metastases without
Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial
Izumi Kouji, Mizokami Atsushi, Namiki Mikio, Inoue Shogo, Tanaka Nobumichi, Yoshio Yuko, Ishibashi Kei, Kamiyama Manabu, Kawai Noriyasu, Enokida Hideki, Shima Takashi, Takahara Shizuko
-free and overall survival for castration-resistant prostate cancer (CRPC) compared with placebo controls before
225 AС-PSMA-617 THERAPY IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Kochetova T.Yu., Krylov V.V., Ivanov S.A., Kaprin A.D.
177 Lu-PSMA-617 is a new therapy option for PSMA-positive metastatic castrate-resistant metastatic
Prognostic Value of BRCA1 and BRCA2 Gene Mutations in Prostate Cancer: a Literature Review
Prognostic Value of BRCA1 and BRCA2 Gene Mutations in Prostate Cancer: a Literature Review
Prediction of survival benefit using an automated bone scan index in patients with castration-resistant prostate cancer
Mitsui Y., Shiina H., Yamamoto Y., Yasumoto H., Kitagaki H., Igawa M., Haramoto M., Arichi N.
Prediction of survival benefit using an automated bone scan index in patients with castration-resistant

Страница 1 из 1400

Фасеты

Новости проекта

Новости

Партнеры

КФУ
ТГУ
Elpub
СФУ
Webpublishers

Индексация

BASE
WorldCat
OpenAIRE
EDS
core